0000890465-13-000025.txt : 20130930 0000890465-13-000025.hdr.sgml : 20130930 20130930182338 ACCESSION NUMBER: 0000890465-13-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130926 FILED AS OF DATE: 20130930 DATE AS OF CHANGE: 20130930 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nader Francois CENTRAL INDEX KEY: 0001365343 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 131124521 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2013-09-26 0000890465 NPS PHARMACEUTICALS INC NPSP 0001365343 Nader Francois 550 HILLS DRIVE BEDMINSTER NJ 07921 1 1 0 0 President, CEO and Director Common Stock 2013-09-26 4 M 0 19350 5.05 A 236828 D Common Stock 2013-09-26 4 M 0 992 5.85 A 237820 D Common Stock 2013-09-26 4 S 0 143503 33.07 D 94317 D Common Stock 2013-09-26 4 S 0 6497 33.60 D 87820 D Common Stock 2013-09-27 4 M 0 17008 5.85 A 104828 D Common Stock 2013-09-27 4 M 0 16650 6.16 A 121478 D Common Stock 2013-09-27 4 M 0 9800 5.71 A 131278 D Common Stock 2013-09-27 4 S 0 43458 32.3558 D 87820 D Stock Options 5.05 2013-09-26 4 M 0 19350 0 D 2018-07-15 Common Stock 19350 3150 D Stock Options 5.85 2013-09-26 4 M 0 992 0 D 2018-10-15 Common Stock 992 21508 D Stock Options 5.85 2013-09-27 4 M 0 17008 0 D 2018-10-15 Common Stock 17008 4500 D Stock Options 6.16 2013-09-27 4 M 0 16650 0 D 2019-01-15 Common Stock 16650 5850 D Stock Options 5.71 2013-09-27 4 M 0 9800 0 D 2019-01-20 Common Stock 9800 82826 D The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective September 26, 2013. The price shown above represents the weighted average price of the shares sold. The range of sales prices was $32.51 and $33.50. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid. The price shown above represents the weighted average price of the shares sold. The range of sales prices was $33.52 and $33.69. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid. The price shown above represents the weighted average price of the shares sold. The range of sales prices was $32.05 and $32.77. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid. On July 15, 2008, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter. On October 15, 2008, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter. On January 15, 2009, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter. On January 20, 2009, the Reporting Person received a grant of performance based options under the Issuer's 1998 Stock Option Plan. The actual number of options received was 92,626, which was determined based on the performance of the Issuer's common stock relative to the performance of stock comprising a selected market index. 50% of such options vested and became exercisable on the second anniversary of the date of grant and the remaining 50% of such options vested and became exercisable on the third anniversary of the date of grant. /s/ Francois Nader, by Edward Stratemeier as attorney-in-fact 2013-09-30